Internal Reference: 2026-082

Market Need

CAR-T therapy has demonstrated transformative clinical efficacy in cancer treatment, yet its broader adoption remains limited. Current approaches require complex, patient-specific ex vivo cell engineering leading to high costs, high infrastructure requirements, long manufacturing timelines, limited scalability and accessibility, and safety concerns associated with permanent genetic modification.

Similarly, emerging in vivo gene delivery strategies using LNPs face an additional limitation – inefficient targeting and transfection of T-cells, largely due to reliance on passive nanoparticle-cell encounters.

Technology Overview

91ɬÂþ has invented an injectable hydrogel-LNP platform that enables on-demand generation of CAR-T cells in vivo. The system integrates three components: T-cell recruiting hydrogel, LNPs engineered to carry mRNA encoding CARs, and in situ cell engineering. This approach transforms CAR-T production from an ex vivo manufacturing process into a localized, T-cell specific, in vivo factory for therapeutic T-cells.

Ìý

Ìý

Commercial Advantages

• Improved accessibility and scalability

• Enhanced safety profile by using non-viral, non-integrating nucleic acids that provide transient CAR expression

• Increased in vivo CAR-T engineering efficiency

• Modular, scalable, and clinically translatable

Additional Information

• Researcher: Guojun Chen
• Validations: in vivo murine melanoma models of immunocompetent mice
• IP Protection: Provisional (Filed April 2026)

Ìý